Meyers BM, Knox JJ, Cosby R, Beecroft JR, Chan KKW, Coburn N, Feld JJ, Jonker D, Mahmud A, Ringash J. Non-surgical management of advanced hepatocellular carcinoma: A systematic review by Cancer Care Ontario.
CANADIAN LIVER JOURNAL 2021;
4:257-274. [PMID:
35992253 PMCID:
PMC9202767 DOI:
10.3138/canlivj-2020-0039]
[Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/26/2020] [Accepted: 01/23/2021] [Indexed: 08/12/2023]
Abstract
Background
Hepatocellular carcinoma (HCC) is a global health problem, accounting for 4.7% of all new cancer cases and 8.2% of all cancer deaths worldwide in 2018. Resection and transplantation are the only modalities that offer a cure for HCC; however, most patients are diagnosed at an advanced stage, precluding these curative treatments. A number of local (ie, ablative therapies) and/or local-regional therapies (ie, chemo-embolization) are used and followed by systemic therapy for advanced or progressive disease. Other treatments are available, but their efficacy compared with these standards is not well known.
Methods
Literature searches (1/2000 to 1/2020 or 1/2005 to 1/2020, depending on the specific systematic review question) were conducted, including MEDLINE, Embase and the Cochrane Database of Systematic Reviews.
Results
Over 30,000 articles were identified. In total, 49 studies were included in the systematic review.
Conclusions
There is no evidence to support the addition of sorafenib to any local or regional therapy. First-line systemic therapy options for unresectable or metastatic HCC include sorafenib, lenvatinib, and atezolizumab + bevacizumab. Regorafenib or cabozantinib provide survival benefits when given as second-line treatment.
Collapse